

New Zealand standardised oral formulation batch sheet

Amlodipine suspension 1 mg/mL (60 mL)

Patient's name			Storage condi	tion	In a refrigerator		А	At room temperature	
NHI			Temperature)	2-8°C			≤ 25°C	
Date compounded			Shelf life		30 days			No data	
Batch number	Batch number		Recommended storage		V			-	
Ingredients required and formula:									
Ingredient	Supplier	Batch number	Expiry date	Star forn	ndard nula	Quantity Dis dispensed by		ispensed Checked by	
Amlodipine 10 mg tablets (besylate)				6	tablets				
Ora-Sweet®	Perrigo			to	60 mL				
Ora-Sweet SF® (sugar can be substituted?	free), Ora-Plus	, Ora-Blend o	r Ora-Blend Si	-®	No *				
Calculations performe	ed by								
Calculations checked									
Area cleared for proc									
Instructions to compound suspension:									
1. Crush tablets in mortar to a fine powder.									
2. Add diluent (Ora-Sweet®) to form a smooth paste.									
3. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.									
4. Make up to the final volume and mix well.									
5. Label and package product appropriately.									
Labels									
Attach product label	and auxiliary lal	bels:						Label	checked by



New Zealand standardised oral formulation batch sheet

Amlodipine suspension 1 mg/mL (60 mL)

		5.5 <u> </u>		· - /				
Final yield		mL Che	cked by					
Final appearance of produ	ct Pale white suspe	Pale white suspension.						
Container	Amber plastic m	Amber plastic mission bottle/ amber glass.						
Compounded by	Name:	Signatu	re:	Date:				
Final check and product re	Name:	Signatu	re:	Date:				
 * Note: Ora-Sweet SF, Ora-Plus, Ora-Blend® or Ora-Blend SF® may cause clumping and are not recommended as diluents. Store in a refrigerator. Shake well before use. 								
 References: Pharmacy Department Canterbury District Health Board. Compounding Formula. Amlodipine 1 mg/1 mL Oral Liquid (20 mL). Canterbury DHB. Original created 09 February 2009. Modified 20 November 2015. Nahata MC, Morosco RS, Hipple TF. J Am Pharm Assoc, 1999; 39(3): 375-7. 								
Prepared by	New Zealand Compounding	nd Compounding Working Group						
Approved by	Medication Safety Expert Ad	cation Safety Expert Advisory Group of Health Quality and Safety Commission NZ						
Hosted by	•	eutical Society of New Zealand Formulations in the Practice Support section of the PSNZ website						

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.

Version approval date

4.0

01/12/21

Version number

Document review due

05/11/19